Aidi Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aidi Gu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Amishi Yogesh Shah
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
38 shared publications - Aradhana M. Venkatesan
Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Tex
38 shared publications - Arlene O. Siefker-Radtke
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
38 shared publications - Ashish M. Kamat
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
38 shared publications - Charles C. Guo
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
38 shared publications - Colin P. N. Dinney
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
38 shared publications
Latest Publications
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in renal cohort A) Overall Survival and B) Progression Free Survival (PFS)
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in renal cohort A) Overall Survival and B) Progression Free Survival (PFS)
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Patient Representativeness Table
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Patient Representativeness Table
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
All Adverse Events in the mRCC cohort regardless of attribution
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
All Adverse Events in the mRCC cohort regardless of attribution
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. B) MIBC cohort.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. B) MIBC cohort.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Consort Diagram for participants in study
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Consort Diagram for participants in study
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
All Adverse Events in the MIBC cohort regardless of attribution
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
All Adverse Events in the MIBC cohort regardless of attribution
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Table 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Efficacy outcomes for the MIBC and mRCC cohorts
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Efficacy outcomes for the MIBC and mRCC cohorts
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Kaplan Meier curves in MIBC cohort A) Overall Survival and B) Relapse Free Survival (RFS)